• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Current perspectives on use of anti-vascular endothelial growth factor agents for retinal disorders.

作者信息

Sengupta Sabyasachi

机构信息

Future Vision Eye Care, Paras Business Centre, Borivali East, Mumbai, Maharashtra, India.

出版信息

Indian J Ophthalmol. 2021 Feb;69(2):209-210. doi: 10.4103/ijo.IJO_72_21.

DOI:10.4103/ijo.IJO_72_21
PMID:33463559
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7933863/
Abstract
摘要

相似文献

1
Current perspectives on use of anti-vascular endothelial growth factor agents for retinal disorders.抗血管内皮生长因子药物用于视网膜疾病治疗的当前观点
Indian J Ophthalmol. 2021 Feb;69(2):209-210. doi: 10.4103/ijo.IJO_72_21.
2
Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.抗血管内皮生长因子治疗视网膜疾病：系统评价和荟萃分析。
BMJ Open. 2019 May 28;9(5):e022031. doi: 10.1136/bmjopen-2018-022031.
3
[The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].[视网膜疾病治疗的革命：阿苏塔眼科研究所的抗血管内皮生长因子治疗]
Harefuah. 2015 Apr;154(4):270-3, 278.
4
Targeted pharmacotherapy of retinal diseases with ranibizumab.雷珠单抗对视网膜疾病的靶向药物治疗
Drugs Today (Barc). 2007 Aug;43(8):529-37. doi: 10.1358/dot.2007.43.8.1120868.
5
Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor.玻璃体内注射抗血管内皮生长因子时疼痛的相关因素。
Eye (Lond). 2018 Sep;32(9):1544-1546. doi: 10.1038/s41433-018-0126-z. Epub 2018 May 17.
6
A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific.抗血管内皮生长因子使用情况的多国比较：美国、英国和亚太地区
Ophthalmol Retina. 2019 Jan;3(1):16-26. doi: 10.1016/j.oret.2018.08.002. Epub 2018 Aug 9.
7
COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.贝伐单抗、阿柏西普和雷珠单抗玻璃体内注射后眼内炎的比较风险。
Retina. 2019 Oct;39(10):2004-2011. doi: 10.1097/IAE.0000000000002351.
8
Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性后的视网膜和脉络膜变化。
Curr Pharm Des. 2019;25(2):184-189. doi: 10.2174/1381612825666190319165824.
9
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.同一天行双侧玻璃体内抗血管内皮生长因子注射：加拿大一大型视网膜中心的经验。
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
10
Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model.贝伐单抗、雷珠单抗和阿柏西普在非人灵长类动物模型中的全身生物分布和玻璃体内药代动力学特性
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5636-5645. doi: 10.1167/iovs.17-22431.

引用本文的文献

1
Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study.新生血管性年龄相关性黄斑变性患者从阿柏西普转换为生物类似药雷珠单抗的疗效观察（TRANSFORM试验）：一项多中心观察性研究
Clin Ophthalmol. 2024 Jun 24;18:1819-1828. doi: 10.2147/OPTH.S459085. eCollection 2024.
2
Efficacy, Safety and Immunogenicity of Sun's Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study.孙氏雷珠单抗生物类似药治疗新生血管性年龄相关性黄斑变性的疗效、安全性及免疫原性：一项3期双盲对照研究
Ophthalmol Ther. 2024 May;13(5):1369-1382. doi: 10.1007/s40123-024-00883-5. Epub 2024 Mar 26.
3
Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes - A multicentric study.印度眼中 Brolucizumab 治疗后眼内炎症的发生率、临床特征、危险因素和结局：一项多中心研究。
Indian J Ophthalmol. 2023 May;71(5):1979-1985. doi: 10.4103/IJO.IJO_2688_22.
4
Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence.雷珠单抗生物类似药与创新药在新生血管性年龄相关性黄斑变性中的对比研究（BALANCE试验）：真实世界证据
Clin Ophthalmol. 2023 Apr 8;17:1067-1076. doi: 10.2147/OPTH.S407219. eCollection 2023.
5
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.随着Razumab™（全球首款生物类似药雷珠单抗）的问世，印度黄斑疾病患者的治疗前景：一项全面综述
Ophthalmol Ther. 2021 Sep;10(3):431-443. doi: 10.1007/s40123-021-00362-1. Epub 2021 Jun 21.
6
Insurance coverage for intravitreal injections in India-The road ahead.印度玻璃体内注射的保险覆盖范围——未来之路
Indian J Ophthalmol. 2021 May;69(5):1027-1028. doi: 10.4103/ijo.IJO_738_21.

本文引用的文献

1
Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathy.在一例息肉样脉络膜血管病变患者中，玻璃体内注射布罗珠单抗后立即发生伴有前房积脓的无菌性眼内炎。
Indian J Ophthalmol. 2021 Feb;69(2):469-470. doi: 10.4103/ijo.IJO_3436_20.
2
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
3
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.Razumab®（CESAR）研究的临床疗效和安全性：我们使用全球首个生物类似药雷珠单抗的经验。
Indian J Ophthalmol. 2021 Feb;69(2):347-351. doi: 10.4103/ijo.IJO_2516_20.
4
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.玻璃体内注射布罗珠单抗后发生的视网膜血管阻塞性血管炎
J Vitreoretin Dis. 2020 Jul;4(4):269-279. doi: 10.1177/2474126420930863. Epub 2020 Jul 1.
5
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.眼内注射布罗鲁单抗后视网膜血管炎和眼内炎症。
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
6
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.HAWK 和 HARRIER：贝鲁珠单抗治疗新生血管性年龄相关性黄斑变性的 3 期、多中心、随机、双盲试验。
Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
7
Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact.玻璃体内注射阿柏西普：临床效果与经济影响
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):561-568. doi: 10.22608/APO.2017263. Epub 2017 Oct 3.
8
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.阿柏西普、贝伐单抗或雷珠单抗治疗糖尿病性黄斑水肿：DRCR.net方案T的近期临床相关研究结果
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. doi: 10.1097/ICU.0000000000000424.
9
Counterfeit Avastin in India: Punish the Criminals, Not the Patients.印度的假冒阿瓦斯汀：惩罚罪犯，而非患者。
Am J Ophthalmol. 2016 Oct;170:228-231. doi: 10.1016/j.ajo.2016.05.023. Epub 2016 Jun 7.
10
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.